...FDA granted Qualified Infectious Disease Product (QIDP) and Fast Track designations to VivaGel BV astodrimer sodium from Starpharma...
...Starpharma Holdings Ltd. (ASX:SPL; OTCQX:SPHRY), Melbourne, Australia Product: VivaGel BV astodrimer sodium (SPL7013) Business: Infectious Nora Weintraub astodrimer sodium SPL7013 Starpharma Holdings Ltd. VivaGel BV...

...The European Commission approved an MAA from Starpharma for VivaGel BV astrodrimer sodium to treat bacterial vaginosis...
...testing to treat recurrent BV. Starpharma Holdings Ltd. (ASX:SPL), Melbourne, Australia Product: VivaGel astodrimer sodium ( SPL7013...

...FDA for a pair of identical, double-blind, placebo-controlled, international Phase III trials to evaluate 1% VivaGel...
...said it plans to start the trials in the next month. Starpharma is also developing VivaGel...
...planned for this half. Starpharma Holdings Ltd. (ASX:SPL; OTCQX:SPHRY), Melbourne, Australia Product: VivaGel astodrimer sodium ( SPL7013...

...Starpharma will begin a double-blind, placebo-controlled, U.S. Phase II trial to evaluate 1% and 3% VivaGel...
...history of recurrent bacterial vaginosis. Starpharma Holdings Ltd. (ASX:SPL; OTCQX:SPHRY), Melbourne, Australia Product: VivaGel ( SPL7013...

...U.S. Phase II trial in 132 patients showed that once-daily 0.5%, 1% and 3% topical VivaGel...
...and odor was shorter for VivaGel compared to placebo. Furthermore, 83% of patients receiving 1% VivaGel...
...placebo. VivaGel was well tolerated. Starpharma Holdings Ltd. (ASX:SPL; OTCQX:SPHRY), Melbourne, Australia Product: VivaGel ( SPL7013...

...began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate 0.5%, 1% and 3% topical VivaGel...
...7 days in 132 patients. Starpharma Holdings Ltd. (ASX:SPL; OTCQX:SPHRY), Melbourne, Australia Product: VivaGel ( SPL7013...

...7 days in 132 patients. Starpharma Holdings Ltd. (ASX:SPL; OTCQX:SPHRY), Melbourne, Australia Product: VivaGel ( SPL7013...

...Corporate Finance managed the placement. Starpharma plans to use the funds for clinical trials of VivaGel...

...VivaGel completely inhibited HIV and HSV-2 infection ex vivo. At 1 and 3 hours post-administration, VivaGel's...
...retained in all women for both viruses. At 12 and 24 hours post-administration, >90% of VivaGel's...
...with no serious adverse events. Starpharma Holdings Ltd. (ASX:SPL; OTCQX:SPHRY), Melbourne, Australia Product: VivaGel ( SPL7013...

...In vitro, SPL7013 inhibited HPV types 16, 18 and 31, which are associated with cervical cancer...
...6 and 11, which are associated with genital warts. SPL7013 is the active ingredient in VivaGel...
...genital herpes and HIV/AIDS transmission. Starpharma Holdings Ltd. (ASX:SPL; Pink:SPHRY), Melbourne, Australia Product: VivaGel ( SPL7013...